EpiBone

• ·EpiBone’s last known valuation is $44.3M (Jan 2020).
• ·It has raised $71.1M across 4 recorded rounds; the latest was Seed Round ($4.3M) in Sep 2025.
• ·Notable investors include Impact Assets, United States Department of War, Alexandria Venture Investments, Hub71, Johnson & Johnson Innovation - JLABS — 50 tracked in total.
• ·1 investment vehicle was formed to buy EpiBone shares in the last 12 months, reporting $1.1M sold to 19 investors, per SEC Form D filings.
• ·EpiBone has filed 3 Form Ds with the SEC since 2020, most recently Dec 2022 ($18.5M sold to 51 investors).
• ·Status: Privately Held (backing).

In the last 12 months, 1 investment vehicle were formed to buy EpiBone shares, reporting $1.1M sold to 19 investors. Most recent filing Mar 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.

Developer of a bone reconstruction technology designed for skeletal reconstruction through three-dimensional design and living cells. The company's technology utilizes a scan of the bone defect and the patient's own stem cells to construct and cultivate a defect-specific autologous-like bone graft, enabling clinicians to provide patients with a bone graft through a simplified surgical procedure, improved bone formation, regeneration, and short recovery times.

Industry

Other Healthcare Technology Systems

Sector

Healthcare

HQ

New York, NY, United States

Founded

2013

Employees

21

Website

epibone.com/

Ownership

Privately Held (backing)